Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric F Morand

Showing results (111-120 of 226) with videos related to

Pageof 23
Sort By:
Journal of Clinical Pharmacology|March 30, 2022
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusYen Lin Chia, Raj Tummala, Tu H Mai, et al.
Lupus Science & Medicine|November 7, 2018
Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosusFabien B Vincent, Laura Slavin, Alberta Y Hoi, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2023
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune DiseasesAnkita Deshmukh, Albertina Pereira, Nicholas Geraci, et al.
Lupus Science & Medicine|April 8, 2026
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trialsAndrea Doria, Ronald F van Vollenhoven, Eric F Morand, et al.
Arthritis and Rheumatism|April 9, 2005
Reduction of arthritis severity in protease-activated receptor-deficient miceYuan H Yang, Pam Hall, Christopher B Little, et al.
Clinical & Translational Immunology|April 19, 2019
Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosisEmily Lin, Fabien B Vincent, Joanne Sahhar, et al.
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1Yuan H Yang, Myew-Ling Toh, Colin D Clyne, et al.
Clinical & Translational Immunology|January 11, 2020
Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosusWilliam A Figgett, Katherine Monaghan, Milica Ng, et al.
Pageof 23

Showing results (111-120 of 226) with videos related to

Sort By:
Pageof 23
Journal of Clinical Pharmacology|March 30, 2022
Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus ErythematosusYen Lin Chia, Raj Tummala, Tu H Mai, et al.
Lupus Science & Medicine|November 7, 2018
Analysis of urinary macrophage migration inhibitory factor in systemic lupus erythematosusFabien B Vincent, Laura Slavin, Alberta Y Hoi, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2023
Preclinical Evidence for the Glucocorticoid-Sparing Potential of a Dual Toll-Like Receptor 7/8 Inhibitor in Autoimmune DiseasesAnkita Deshmukh, Albertina Pereira, Nicholas Geraci, et al.
Lupus Science & Medicine|April 8, 2026
Efficacy and safety of anifrolumab in patients with systemic lupus erythematosus without prior immunosuppressant use: post hoc analysis of phase 3 TULIP-1 and TULIP-2 trialsAndrea Doria, Ronald F van Vollenhoven, Eric F Morand, et al.
Arthritis and Rheumatism|April 9, 2005
Reduction of arthritis severity in protease-activated receptor-deficient miceYuan H Yang, Pam Hall, Christopher B Little, et al.
Clinical & Translational Immunology|April 19, 2019
Analysis of serum interleukin(IL)-1α, IL-1β and IL-18 in patients with systemic sclerosisEmily Lin, Fabien B Vincent, Joanne Sahhar, et al.
Arthritis Care & Research|April 28, 2026
Discordance between systemic lupus erythematosus disease activity index domain weights and their association with organ damage accrualKevin Zhang, Eric F Morand, Sarah E Boyd, et al.
Rheumatology (Oxford, England)|August 26, 2022
Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trialsIan N Bruce, Ronald F van Vollenhoven, Eric F Morand, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 23, 2006
Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1Yuan H Yang, Myew-Ling Toh, Colin D Clyne, et al.
Clinical & Translational Immunology|January 11, 2020
Machine learning applied to whole-blood RNA-sequencing data uncovers distinct subsets of patients with systemic lupus erythematosusWilliam A Figgett, Katherine Monaghan, Milica Ng, et al.
Pageof 23